Effect of Early Tumor Necrosis Factor Inhibitor Initiation on Chronic Opioid Use in Individuals With Axial Spondyloarthritis
Arthritis Care & Research · 2026
DOI: 10.1002/acr.25659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Eva Petrow und 6 weiteren Autor:innen. Beteiligte Einrichtung: Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts. Hauptthemen laut MEDLINE: Analgesics, Opioid, Tumor Necrosis Factor Inhibitors, Axial Spondyloarthritis, Tumor Necrosis Factor-alpha. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAMS NIH HHS, Rheumatology Research Foundation.
Abstract (Originalsprache)
Objective
Opioid use remains common despite effective therapies for axial spondyloarthritis (axSpA). We assessed whether early tumor necrosis factor inhibitor (TNFi) use is associated with reduced risk of chronic opioid use.
Methods
Using the Merative MarketScan Commercial Database containing health insurance billing claims data, we conducted a time‐stratified, propensity score (PS)–matched cohort study of adults aged 18 to 65 years with axSpA. Early TNFi exposure was defined using pharmacy and medical claims as any incident TNFi use within 6 months of axSpA diagnosis. We used PSs to match early TNFi users 1:1 to those not starting a TNFi within 6 months in 1‐year cohort accrual blocks. We compared the risk of chronic opioid use (≥90 days’ prescription) among early TNFi users versus comparators using Cox proportional hazard models, overall and stratified by prior opioid use (within 12 months).
Results
We included 8,508 individuals with axSpA after PS matching (4,254 early TNFi initiators and 4,254 comparators) with a mean age of 42 years; 50% were female. Chronic opioid use occurred in 20.9% (22.3% early TNFi initiators and 19.6% comparators). Early TNFi initiators had 17% higher risk of chronic opioid use versus matched comparators (95% confidence interval [CI] 1.06–1.28), with higher risk of chronic opioid use for early TNFi initiators in the opioid‐naive but not in the opioid‐experienced stratum (hazard ratio [HR] 1.96; 95% CI 1.41–2.74 vs HR 1.06; 95% CI 0.96–1.17).
Conclusion
Early TNFi initiation was not associated with reduced risk of chronic opioid use versus later or no TNFi initiation. Confounding by indication in administrative claims data limit result interpretation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
- Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
- VA Boston Healthcare System, Boston, Massachusetts.
ORCID-Profile: Eva Petrow, Jose A Meade-Aguilar, S Reza Jafarzadeh, Tuhina Neogi, Maureen Dubreuil, Jean Liew
Förderung
- NIH HHS
- NIAMS NIH HHS
- Rheumatology Research Foundation
- Spondylitis Association of America
- ARTHFN
- Spondyloarthritis Research and Treatment Network
- Clinical and Translational Science Institute, Boston University
- Arthritis Foundation
Zitieren
APA
Petrow, E., Meade-Aguilar, J. A., Peloquin, C., Jafarzadeh, S. R., Neogi, T., Dubreuil, M., & Liew, J. (2026). Effect of Early Tumor Necrosis Factor Inhibitor Initiation on Chronic Opioid Use in Individuals With Axial Spondyloarthritis. Arthritis Care & Research. https://doi.org/10.1002/acr.25659
Vancouver
Petrow E, Meade-Aguilar JA, Peloquin C, Jafarzadeh SR, Neogi T, Dubreuil M, et al. Effect of Early Tumor Necrosis Factor Inhibitor Initiation on Chronic Opioid Use in Individuals With Axial Spondyloarthritis. Arthritis Care & Research. 2026. doi:10.1002/acr.25659
BibTeX
@article{Petrow2026,
author = {Petrow, Eva and Meade-Aguilar, Jose A and Peloquin, Christine and Jafarzadeh, S Reza and Neogi, Tuhina and Dubreuil, Maureen and Liew, Jean},
title = {Effect of Early Tumor Necrosis Factor Inhibitor Initiation on Chronic Opioid Use in Individuals With Axial Spondyloarthritis},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.25659}
}
EUVIMED